Add like
Add dislike
Add to saved papers

Predetermination of burst times of elastoplastic osmotic capsules.

"Pulsed drug release" for dosing drugs such as vaccines, hormones etc. that require multiple, pre-determined release events can be obtained by using capsules that exploit the principle of osmosis to achieve a delayed-burst release of their payload. An objective of this study was to precisely determine the lag-time before burst which occurs when the hydrostatic pressure developed due to water influx expands the capsule shell to rupture. A novel 'dip-coating' technique was used to encapsulate osmotic agent solution or solid within biodegradable poly(lactic acid-co-glycolic) (PLGA) spherical capsule shells. As a prelude to determine the hydrostatic pressure to burst, first, elastoplastic and failure characterization of PLGA was conducted by a novel "beach ball inflation" technique. The lag time before burst of various capsule configurations was pre-determined by modeling the rate of water uptake by the capsule core as a function of capsule shell thickness, radius of the sphere, core osmotic pressure, and the membrane's hydraulic permeability and tensile properties. In vitro release was studied with capsules of different configurations to determine their actual time to burst. The time to rupture pre-determined from the mathematical model corroborated with the in vitro results and was found to increase with increases in capsule radius and shell thickness and decrease in osmotic pressure. Pulsatile drug delivery can be achieved by using a multitude of these osmotic capsules consolidated in a single system, each programmed to release the drug payload after a pre-determined time lag.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app